Palivizumab prophylaxis, respiratory syncytial virus and subsequent development of asthma

Igde M., Kabasakal H., Ozturk O., Karatekin G., Aygun C.

MINERVA PEDIATRICA, cilt.70, sa.3, ss.252-259, 2018 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 70 Sayı: 3
  • Basım Tarihi: 2018
  • Doi Numarası: 10.23736/s0026-4946.16.04368-1
  • Dergi Adı: MINERVA PEDIATRICA
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.252-259
  • Anahtar Kelimeler: Palivizumab, Prevention and control, Asthma, Respiratory syncytial virus infections, PREMATURE-INFANTS, RSV BRONCHIOLITIS, FOLLOW-UP, INFECTION, RIBAVIRIN, ALLERGY, RISK, IGE, CHILDREN, THERAPY
  • Ondokuz Mayıs Üniversitesi Adresli: Evet

Özet

BACKGROUND: Respiratory syncytial virus (RSV) infection is a disease commonly encountered during childhood and it may relapse. An experience in the early childhood would induce asthma development in the future. Palivizumab has a proven efficacy for the RSV prophylaxis so it may prevent asthma. Our aim was to evaluate the possible protective effect of palivizumab on the development of asthma by using the modified Asthma Predictive Index (mAPI).